Details of Disease

Disease Name

Hepatic coma

hepatocerebral intoxication

Definition

A syndrome characterized by central nervous system dysfunction in association with liver failure, including portal-systemic shunts. Clinical features include lethargy and confusion (frequently progressing to coma); asterixis; nystagmus, pathologic; brisk oculovestibular reflexes; decorticate and decerebrate posturing; muscle spasticity; and bilateral extensor plantar reflexes (see reflex, babinski). electroencephalography may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Disease Hierarchy

DISEAKAN: Hepatic encephalopathy

DISILSPO: Hepatic coma

Disease Identifiers

MONDO ID

MONDO_0001548

MESH ID

D006501

UMLS CUI

C0019147

MedGen ID

6803

SNOMED CT ID

72836002

General Information of Disease (ID: DISILSPO)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Erythromycin	DM4K7GQ	Approved	Small molecular drug	[1]
Framycetin	DMF8DNE	Approved	Small molecular drug	[2]
Paromomycin	DM1AGXN	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GABRA1	TT1MPAY	Strong	Biomarker	[4]
GABRG2	TT06RH5	Strong	Biomarker	[4]
GLUL	TTURQ2G	Strong	Biomarker	[5]
LTA	TTP73TM	Strong	Biomarker	[6]
MAOA	TT3WG5C	Strong	Biomarker	[5]
MAOB	TTGP7BY	Strong	Biomarker	[5]
NOS1	TTZUFI5	Strong	Biomarker	[5]
OPRM1	TTKWM86	Strong	Biomarker	[7]
PRKDC	TTK3PY9	Strong	Biomarker	[8]
TSPO	TTPTXIN	Strong	Biomarker	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DTT(s)

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GABRB1	OT4L2SSB	Strong	Biomarker	[4]
GC	OTWS63BY	Strong	Biomarker	[9]
------------------------------------------------------------------------------------

References

1	Erythromycin FDA Label
2	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3	Paromomycin FDA Label
4	Expression of gamma-aminobutyric acid A receptor subunits alpha1, beta1, gamma2 mRNA in rats with hepatic encephalopathy.World J Gastroenterol. 2005 Jun 7;11(21):3319-22. doi: 10.3748/wjg.v11.i21.3319.
5	Hepatic encephalopathy: An update of pathophysiologic mechanisms.Proc Soc Exp Biol Med. 1999 Nov;222(2):99-112. doi: 10.1046/j.1525-1373.1999.d01-120.x.
6	Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure.J Hepatol. 1998 Jul;29(1):53-9. doi: 10.1016/s0168-8278(98)80178-5.
7	Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure.Life Sci. 2002 Feb 22;70(14):1701-8. doi: 10.1016/s0024-3205(02)01487-x.
8	Perturbations in ataxia telangiectasia mutant signaling pathways after drug-induced acute liver failure and their reversal during rescue of animals by cell therapy.Am J Pathol. 2011 Jan;178(1):161-74. doi: 10.1016/j.ajpath.2010.11.001. Epub 2010 Dec 23.
9	Temporal profile of total, bound, and free Gc-globulin after acetaminophen overdose.Liver Transpl. 2001 Aug;7(8):732-8. doi: 10.1053/jlts.2001.26061.